Navigation Links
Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights
Date:8/7/2008

with dacarbazine in patients identified by a biomarker who have not previously received chemotherapy. The co-primary endpoints of AGENDA are progression-free survival and overall survival. This global trial is targeting the recruitment of 300 patients from Europe, the U.S., Canada, and Australia.

Genasense in Chronic Lymphocytic Leukemia (CLL): During the quarter, Genta submitted an amendment to its New Drug Application (NDA) for the use of Genasense plus chemotherapy in patients with relapsed/refractory CLL. The submission was based primarily on new information from the Company's completed, randomized Phase 3 trial that showed, among other findings, a significant increase in overall survival for patients who achieved a complete or partial response when treated with Genasense plus chemotherapy compared with patients treated with chemotherapy alone. Subsequently, FDA has notified the Company that it considers Genta's submission as a complete response and a Class 2 resubmission with a Prescription Drug User Fee Act (PDUFA) goal date for FDA's response of December 3, 2008. The submission requests marketing approval of Genasense for the proposed indication.

Tesetaxel: A Leading Oral Taxane with Anticancer Activity

In other regulatory activity, Genta submitted its response to a prior notice from FDA that had placed tesetaxel, a clinical-stage oral taxane, on full "clinical hold". During the quarter, the Company was notified by FDA that the clinical hold had been lifted and that Genta may resume clinical trials with tesetaxel.

Tesetaxel is the latest addition to the Genta oncology portfolio. The agent was developed to avoid serious effects associated with other taxanes (such as paclitaxel [Taxol(R); Bristol Myers Squibb] and docetaxel [Taxotere(R); sanofi aventis]), including severe infusion reactions, peripheral nerve damage, and drug resistance. More than 250 patients have received tesetaxel, and the drug has demonstrated anticancer activity
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Genta Announces Second Quarter 2008 Financial Results and Conference Call
2. Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
3. Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
4. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
5. Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
6. Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
7. Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
8. Dr. Elizabeth Brown Joins Argenta TEC
9. Syngenta To Build Major Global Biotech Research Center in Beijing, China
10. Genta Restructures Operations to Focus on Priority Initiatives
11. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... D.C. (PRWEB) September 18, 2014 On ... Durbin and Sen. Jim Risch for National Lab Day ... projects from across the national laboratory system. Durbin and ... which aims to increase awareness of the reach of ... technologies and discoveries to address some of our nation's ...
(Date:9/18/2014)... -- Research and Markets has announced ... Report 2014" report to their offering. ... is a professional and in-depth study on the ... The report provides a basic overview of ... chain structure. The N-acetylcysteine market analysis is provided ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ ... report to their offering. The ... a CAGR of 22.7% from 2014 to 2019. Factors ... treatment, growing adoption of companion diagnostics by the pharmaceutical ...
(Date:9/18/2014)... Sept. 18, 2014  U.S. biotech company Kultevat ... exclusive license for technology developed by the Donald ... in plants, including for applications in production of natural ... The technology was developed under the direction of ... and former president of the Danforth Plant Science Center, ...
Breaking Biology Technology:Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global N-acetylcysteine Industry Report 2014 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Kultevat obtains license of gene switch technology 2
... my wishes are,coming true," says Kristin Shumpert, who is traveling from ... of Las,Vegas ... and to meet the people who "saved my ... held little interest to the young,woman who suffers from a devastating ... time to use the ladies, room. , ...
... Integrated Knowledge Center Outside the United States. , ... ... Knowledge Center (DKC) today, 17 months after breaking ground last summer. ... the city’s Genome Valley, the center will be a research hub ...
... commercial life sciences sales experience to Cyntellect , ... a privately-held life sciences company leading the development and commercialization ... it has appointed Andre Lubarsky as the Company,s Director of ... sales of Cyntellect,s cell purification and cell health products in ...
Cached Biology Technology:Noninvasive Medical Technologies Helps Make Young Tennessee Woman's Wishes Come True 2Noninvasive Medical Technologies Helps Make Young Tennessee Woman's Wishes Come True 3Noninvasive Medical Technologies Helps Make Young Tennessee Woman's Wishes Come True 4Noninvasive Medical Technologies Helps Make Young Tennessee Woman's Wishes Come True 5DuPont Opens Research & Development Center in India 2DuPont Opens Research & Development Center in India 3Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America 2
(Date:9/18/2014)... AZ, Sept. 18, 2014 -- Arizona turned its newborn ... just a few short months, earning it the first-ever Newborn ... The March of Dimes presented Will Humble, M.P.H., Arizona,s Department ... held here today. Mr. Humble established a policy of full ... to send newborn blood samples to the lab for analysis, ...
(Date:9/18/2014)... will be celebrated tonight at the third annual Golden ... health of premature infants and in paving the way ... work was supported by the National Science Foundation, the ... Commission, will be honored at a ceremony at the ... of Members of Congress will be on hand to ...
(Date:9/18/2014)... September 18, 2014 Elsevier, a world-leading provider ... services, and the Australasian Research Management Society (ARMS), ... scientists at the 5th Scopus Young Researcher of ... earlier today at the National Convention Centre and ... was attended by guests representing Australia,s and New ...
Breaking Biology News(10 mins):March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 33rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2
... fluctuations in the populations they target, but its not ... journal Nature by scientists at Scripps Institution of Oceanography ... general underlying mechanism. Research led at Scripps with ... two chief scientific advisors to the United Kingdom) demonstrates ...
... worm, University of Maryland researchers have discovered an important ... absorbed and transported into the body. The finding could ... the worlds number one nutritional disorder., With C. elegans, ... Hamza, assistant professor of animal and avian sciences, and ...
... -- Some primates have evolved big brains because their ... advantage that outweighs the demands of extra years of ... Duke University and the University of Zurich have concluded ... key benchmarks in the development of 28 different primate ...
Cached Biology News:Fishing throws targeted species off balance, Scripps study shows 2Fishing throws targeted species off balance, Scripps study shows 3Bloodless worm sheds light on human blood, iron deficiency 2Bloodless worm sheds light on human blood, iron deficiency 3Slowly-developing primates definitely not dim-witted 2Slowly-developing primates definitely not dim-witted 3
Mouse monoclonal antibody to Lats2....
... (eIF4E-binding protein II) is involved in translation ... kidney. PHAS proteins bind to eIF-4E, the ... capped mRNA in vitro and in cells. ... of PHAS/eIF-4E complexes. This allows eIF-4E to ...
MAb to HSV-2, gG-2 HSV-2 Glycoprotein G-2...
... INK4a-ARF locus encodes two unrelated proteins both ... arrests the cell cycle in a p53-dependent ... the rapid degradation of mdm2 proteinrequired for ... accumulation. This interaction is mediated by ...
Biology Products: